



✉ EPA/EPO/OEB
D-80298 München
☎ +49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

**Europäisches
Patentamt**

Generaldirektion 2

**European
Patent Office**

Directorate General 2

**Office européen
des brevets**

Direction Générale 2

Vossius & Partner
Siebertstrasse 4
81675 München
ALLEMAGNE

Telephone numbers:

Primary Examiner +49 89 2399-8785
(substantive examination)

Formalities Officer / Assistant +49 89 2399-5762
(Formalities and other matters)



Application No. 04 772 194.9 - 2405	Ref. M1335 EP S3	Date 15.11.2007
Applicant TAKARA BIO INC.		

Communication pursuant to Article 96(2) EPC

The examination of the above-identified application has revealed that it does not meet the requirements of the European Patent Convention for the reasons enclosed herewith. If the deficiencies indicated are not rectified the application may be refused pursuant to Article 97(1) EPC.

You are invited to file your observations and insofar as the deficiencies are such as to be rectifiable, to correct the indicated deficiencies within a period

of 4 months

from the notification of this communication, this period being computed in accordance with Rules 78(2) and 83(2) and (4) EPC.

One set of amendments to the description, claims and drawings is to be filed within the said period on separate sheets (Rule 36(1) EPC).

Failure to comply with this invitation in due time will result in the application being deemed to be withdrawn (Article 96(3) EPC).



Obel, Nicolai
Primary Examiner
for the Examining Division

Enclosure(s): 5 page/s reasons (Form 2906)

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 1
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

The examination is being carried out on the following application documents:

Description, Pages

1-189 as originally filed

Sequence listings, Pages

1-46 as originally filed

Claims, Numbers

1-20 received on 29.08.2007 with letter of 29.08.2007

Drawings, Sheets

1 as originally filed

1. New claims 1-20 filed with your letter dated 29.08.2007 are not allowable under Article 123(2) EPC.

1.1 Claim 1 of the amended claims is describing subject matter beyond the application as filed. The claim refers to SEQ ID NO 9 to 20 and 25 or "a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m)". The basis is claimed to be found in claims 10 and 12 of the original set of claims.

**Bescheld/Protokoll (Anlage)**

Datum
Date
Date 15.11.2007

Communication/Minutes (Annex)

Blatt
Sheet
Feuille 2

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

However, the variants of the sequences are described in claim 10 and are with regard to SEQ ID NO 1-8. No variants of SEQ ID NO 9 and 20-25 are disclosed in claim 12 of the original set of claims. The fact that the original claim 12 was dependent on claim 10 can not serve as a basis as SEQ ID NO 9 and 20-25 represent specific embodiments within the scope of claim 10 of the original set of claims. The amendment describes thus subject matter beyond the application as filed.

- 1.2 The claims 1,6,13,14 and 15 are directed to a method using "a fibronectin fragment or a mixture thereof", see also 4.2. The original set of claims were describing "fibronectin, a fragment thereof or a mixture thereof". The basis is thus disclosing a mixture of fibronectin and a fibronectin fragment. The amended set of claims can only be seen as describing a mixture of at least two different fibronectin fragments and describe thus subject matter beyond the application as filed.
2. The present application does not meet the requirements of Article 52(1) EPC, because the subject-matter of claims 1,3-10,15 and 16 is not new in the sense of Article 54(1) and (2) EPC.
 - 2.1 It is acknowledged that the amendments to claims 1 and 15 render the subject matter novel with regard to D1,D2,D5 and D7 as a serum concentration in the range 0-4% is not disclosed in said documents. Furthermore, the protein and nucleic acid sequences disclosed in the amended claims 18-20 is not disclosed in D3 and D4.
 - 2.2 In the letter of 29.08.07, the applicant argues that D6 does not disclose the new features in the amended claim 1 which refer to the expansion of cells and the use of fibronectin fragments. However this is not correct as D6 (col 19 l. 61- col 20 l. 45) discloses a method of growing cytotoxic lymphocytes such as LAK's in the presences of an extracellular matrix protein such as fibronectin placed on a membrane. D6 (col 31 l. 51 - col 32 l. 4) discloses also that cells were bound to a proteolytic fragment of fibronectin and the binding was inhibited by 90% by RGDS, the central binding site of fibronectin (D6, col 32 l. 65 - col 33 l. 37). The document discloses thus that the binding was restricted to distinct fragments of fibronectin. D6 states also that serum free medium can be used (col 5 l. 15-28) and that mainly CD8+ cells were generated (col 16 l. 49-61, col 26 l. 10-21, col 30 l. 23-28).

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 3
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

D6 is directed to a method of providing activated T-lymphocytes for use in therapy. The vague definition of the fibronectin fragments to be used in the method, which is not conform with Article 123(2) and 84 EPC, see 1.1 and 4.1, means that no limitations with regard to the indicated sequences exist beyond the fibronectin annotation. D6 anticipates thus the subject matter of claims 1,3-10,15 and 16 of the amended set of claims.

3. The present application does not meet the requirements of Article 52(1) EPC, because the subject-matter of claims 2,11-14 and 17-20 does not involve an inventive step in the sense of Article 56 EPC.
- 3.1 The document D6 is regarded as being the closest prior art to the subject-matter of claims 2,11-14 and 17, see 2.2.

The subject matter of claim 2 is directed to a method for providing cytotoxic lymphocytes by expanding the cells on fibronectin fragments and thereby increase the expression of the IL-2 receptor.

The subject-matter of claim 2 therefore differs from this known (D6) in that the method provides a higher expression of the IL-2 receptor.

The problem to be solved can thus be regarded at to provide an improved method for providing cytotoxic lymphocytes.

D6 already provides a method for expanding cytotoxic lymphocytes on fibronectin fragments and D5 (abstract) discloses that exposure to fibronectin increased the expression of the IL-2 receptor. The subject matter of claim 2 is thus not regarded as inventive in the sense of Article 56 EPC.

In the letter of 29.08.2007, the applicant argues that surprising effects arise from the disclosed method. These effects are a high expression of the IL-2 receptor, an increased expansion rate, increased cytotoxicity and higher ratio of CD8+ cells. If such improvements were clearly demonstrated with regard to the prior art an inventive step could be acknowledged. However, no surprising effects have been

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 4
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

substantiated with data, documenting said alleged effects.

- 3.2 D1,D5 and D7 do not anticipate claims 1 and 15 of the amended set of claims. However, the only difference to these documents and the subject matter of claim 1 is the lowering of the serum concentration from 5% to 4%. The objective problem to be solved with regard to said documents would thus be how to provide an alternative method for producing cytotoxic lymphocytes. Since it is evident for the person skilled in the art that it is beneficial for patients if less serum is used, the lowering of the serum concentration from 5% to 4% can not be considered inventive. Similar to 3.1, an inventive step with regard to said claims can be acknowledged if a surprising or unexpected effect is documented.
- 3.3 Claims 11-14 is directed to specific steps and concentrations of cells when culturing the cytotoxic lymphocytes. Said steps and concentrations are all normally used in the art and in view of 3.1 the subject matter is not inventive in the sense of Article 56 EPC.
- 3.4 Claim 17 differs from D6 in the use of retro-virus or adeno-associated virus for gene transduction. These methods for gene transduction are merely some of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed. In view of 3.1, the subject matter of claim 17 is not inventive in the sense of Article 56 EPC.
- 3.5 The subject matter of claims 18-20 differs from the prior art (D4) in that only a partial sequence of the fibronectin disclosed in D4 is selected. D4 (p. 3 l. 8-22) states that also fragments extending from the core 277-577 amino acids are encompassed by D4. The subject matter of claims 18-20 is thus merely representing an arbitrary selection of the sequence disclosed in D4. No surprising or unexpected effect has been documented for this molecule with regard to other fibronectin fragments and the subject matter is thus not inventive in the sense of Article 56 EPC.
4. The application does not meet the requirements of Article 84 EPC, because claims 1,6 and 15 are not clear.

**Bescheld/Protokoll (Anlage)**

Datum
Date
Date 15.11.2007

Communication/Minutes (Annex)

Blatt
Sheet
Feuille 5

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

- 4.1 If a basis is indicated for the amended claim 1 in its present form, the applicant should notice that the claim is not clear due to the term "at least one amino acid sequence having substitutions, deletions, insertions or additions of one or more plural number of amino acids". This term is not suitable to clearly define the scope of the claim, because without definition of the length of the fragment, degree of identity and precise definition of the meant portion of the molecule this expression is absolutely vague and ambiguous. The claim encompass all fibronectin fragments regardless of the indicated sequences.
- 4.2 Claims 1,6 and 15 are not clear as they are directed to "a fibronectin fragment or a mixture thereof". The indicated "mixture thereof" is not clear as it can not be ascertained what the mixture consists of as only a fibronectin fragment, i.e one fragment, is indicated as being used for cell expansion.
5. The applicant is requested to file new claims which take account of the above comments. The attention of the Applicant is drawn to the fact that the application may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed, Article 123(2) EPC.

VOSSIUS & PARTNER



Patentanwälte Rechtsanwälte

EPO - Munich
40

29. Aug. 2007

VOSSIUS & PARTNER * POB 86 07 67 * 81634 München * Germany

European Patent Office

80298 MUNICH

EP 04 77 2194.9-2405

Takara Bio Inc.

Our Ref.: M1335 EP S3

Munich, August 29, 2007

SZ/AF

This is in response to the Communication pursuant to Article 96(2)
EPC dated February 20, 2007.

Enclosed please find new claims 1 to 20 which should form the
basis for further substantive examination. We herewith reserve our
right to file divisional applications for subject matter which was
deleted from the claims or which is no longer covered by the new
claims.

1. AMENDMENTS IN THE CLAIMS

1.1 New claim 1 is based on original claim 1 which has been
amended as follows:

- (i) The term "a cytotoxic lymphocyte" has been corrected
to "cytotoxic lymphocytes".
- (ii) The phrase "at least one step selected from induction,
maintenance and" has been deleted and the term "an"
has been inserted before "expansion".

PATENTANWÄLTE EUROPEAN PATENT ATTORNEYS EUROPEAN TRADEMARK ATTORNEYS

DR. VOLKER VOSSIUS, Dipl.-Chem.
(bis 1992; danach in anderer Kanzlei)
DR. PAUL TAUCHNER, Dipl.-Chem.
DR. DIETER HEUNEMANN, Dipl.-Phys. *
DR. PETER A. RAUH, Dipl.-Chem.
DR. GERHARD HERMANN, Dipl.-Phys.
JOSEF SCHMIDT, Dipl.-Ing.
DR. HANS-RAINER JAENICHEN, Dipl.-Biol.
DR. ALEXA V. UEXKÜLL, M.Sc.
DR. RUDOLF WEINBERGER, Dipl.-Chem.
AXEL STELLBRINK, Dipl.-Ing.
DR. JOACHIM WACHENFELD, Biol.
DR. FRIEDRIKE STOLZENBURG, Dipl.-Biol.
RAINER VIKTOR, Dipl.-Ing.
DR. NATALIA BERRYMAN, Dipl.-Chem.
DR. JÖRG MEIER, Dipl.-Biol.
DR. STEFAN FICKERT, Dipl.-Chem.
ARNOLD ASMUSSEN, Dipl.-Ing.
ELARD SCHENCK ZU SCHWEINSBERG, Dipl.-Ing.
DR. KATHARINA HAAS, Dipl.-Chem.
DR. CHRISTIAN KILGER, Dipl.-Biol. *
DR. UTE KILGER, Dipl.-Chem. *
DR. DIRK HARMSEN, Dipl.-Chem.

EUROPEAN PATENT ATTORNEYS

DR. RENATE BARTH, Dipl.-Chem.
DR. URSULA ENGBRECHT, Dipl.-Chem.
DR. PETER EINMAYR, Dipl.-Chem.
DR. WERNER BASTIAN, Dipl.-Biol. **
DR. OLAF MALEK, Dipl.-Biol.
DR. MICHAELA WESSE, Apothekerin
DR. ANDREAS KOCH, Dipl.-Biol.
DR. OLIVER SAHR, Dipl.-Phys.
DR. GERHARD WEINZIERL, Dipl.-Biol.
DR. AXEL LEINS, Dipl.-Phys.
THOMAS RITTER, Ph.D., M.Sc.

RECHTSANWÄLTE

DR. JOHANN PITZ
BARBARA GUGGENMOS, Dipl.-Chem.
DR. THURE SCHUBERT
SIMONE SCHÄFER
JENNIFER CLAYTON-CHEN
DR. NIELS HOLDER, LL.M.
DR. MATHIAS KLEESPIES, LL.M.

CONSULTANTS

HELGA TREMMEL, RECHTSANWÄLTIN
DR. CHRISTIAN GUGERELL,
EUROPEAN PATENT ATTORNEY
YOSHIKAZU ISHINO
KIMIO TAKAHASHI

MAIN OFFICE

SIEBERTSTR. 3
81675 MÜNCHEN/GERMANY

POSTAL ADDRESS:

POB 86 07 67
81634 MÜNCHEN/GERMANY

Tel.: +49-(0)89-413 04-0
Fax: +49-(0)89-413 04-111
Fax trademarks: /-400

BRANCH OFFICE BERLIN *

JOACHIMSTALER STR. 34
10719 BERLIN/GERMANY

Tel.: +49-(0)30-340 609-501
Fax: +49-(0)30-340 609-512

Partnerschaftsregister Amtsgericht München PR 89

BRANCH OFFICE BASEL (CH) **

GRELLINGERSTR. 60
4052 BASEL/SWITZERLAND

Tel.: +41-(0)61 560 1490
Fax: +41-(0)61 560 1488

HR Firmennummer CH-270.9.001.271-9

E-Mail:

patents@vossiusandpartner.com
trademarks@vossiusandpartner.com

www.vossiusandpartner.com

(iii) "5% by volume" has been amended to "4% by volume".

Support for this amendment can be found, e.g. on page 22, lines 22 to 24 of the application.

(iv) The phrase "fibronectin, a fragment thereof or a mixture thereof" has been restricted to "a fibronectin fragment or a mixture thereof".

(v) Moreover, the fibronectin fragment has been further specified as one consisting of SEQ ID NOs: 9 to 20 or 25 or as a polypeptide deviation from these fragments but having a function equivalent to SEQ ID NOs: 9 to 20 or 25.

Support for this amendment can be found, e.g., in original claims 10 and 12.

1.2 New claims 2 to 5 correspond to original claims 2 to 5 with the only exception that the following amendments have been effected:

(i) The term "cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes".

(ii) It has been clarified that the method is for preparing cytotoxic lymphocytes with the indicated activities/properties.

1.3 New claim 6 corresponds to original claim 6 which has been restricted to the fibronectin fragments mentioned in claim 1.

1.4 New claims 7 and 8 correspond to original claims 7 and 8.

1.5 New claim 9 corresponds to original claim 9 with the only exception that the singular has been corrected to plural.

1.6 Original claim 10 has been deleted.

1.7 New claim 10 corresponds to original claim 11 with the back reference adjusted.

1.8 Original claim 12 has been deleted.

1.9 New claim 11 corresponds to original claim 13.

1.10 New claim 12 corresponds to original claim 14 with the back reference adjusted.

- 1.11 New claims 13 and 14 correspond to original claims 15 and 16, respectively, wherein "at least any one of induction, maintenance and" has been deleted, "an" has been inserted before "expansion", "a cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes" and the claims have been restricted to fibronectin fragments.
- 1.12 Original claims 17 and 18 have been deleted.
- 1.13 New claim 15 corresponds to original claim 19 in which the same amendments as set forth in section 1.1(i), (iii) and (iv) for claim 1 have been effected.
- 1.14 New claim 16 corresponds to original claim 20 in which "a cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes" and the back reference has been adjusted.
- 1.15 New claim 17 corresponds to original claim 21 with the back reference adjusted.
- 1.16 New claim 18 corresponds to original claim 22 in which the term "having" has been replaced by "consisting of" and the phrase "of one or the plural number of amino acid(s)" has been replaced by "of 1-20 amino acids".
Support for the latter amendment can, e.g. be found on page 48, lines 1 to 5 of the application.
- 1.17 New claim 19 corresponds to original claim 23 with the back reference adjusted.
- 1.18 New claim 20 corresponds to original claim 24 with the exception of the following amendments:
- (i) The "comprising" language has been replaced by "consisting" language.
 - (ii) The back reference has been adjusted.
 - (iii) The phrase "of one or the plural number of nucleotide(s)" has been replaced by "of 1-60 nucleotides".
This amendment is, e.g., supported by the disclosure content provided on page 48, last line to page 49, line 4.
 - (iv) Part (3) has been deleted.

For the convenience of the Examiner we enclose a copy of the claims from which the effected amendments are evident.

2. NOVELTY (ARTICLE 54 EPC)

2.1 Claims 1 and 19 (new claims 1 and 15)

(a) EP-A1 1 424 387 (D1)

In section 2.1 of the Communication original claims 1 and 19 are objected to as lacking novelty over EP-A1 1 424 387 (D1) in particular in view of the disclosure provided in paragraph 165 in combination with paragraph 77 and in view of claim 8 of D1.

This novelty objection does not apply to the new claims. It has been specified in the claims that the serum and plasma concentration in the medium is between 0% by volume and less than 4% by volume. This feature is not disclosed in D1. The medium used in D1 contains 5% serum as is evident from paragraph [0077], line 26 in connection with paragraph [0165]. Thus, new claims 1 and 15 are novel over D1.

(b) Cardarelli (D5)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over Cardarelli (D5), in particular the disclosure provided in the "Materials and Methods" section.

This objection does not apply to the new claims. In particular, the claims have been restricted to the use of certain fibronectin fragments. D5, however, does not disclose the use of fibronectin fragments. Thus, new claims 1 and 15 are novel over D5.

(c) US 5,354,686 (D6)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over US 5,354,686 (D6).

However, we submit that this novelty objection is not justified and, in particular, does not apply to the new claims for the following reasons: D6 relates to T-cells which are capable of binding to an extra-cellular matrix protein (ECM protein) such as fibronectin. However, it fails to teach or suggest effects by using fragments of fibronectin. Also, this reference merely discloses to assess the likelihood of binding of T-cells to fibronectin as ECM with serum-free cell culture medium, but it does not disclose expanding T-cells with serum-free culture medium.

Thus, new claims 1 and 15 are also novel over D6.

(d) Takashi (D7)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over Takashi (D7).

However, we submit that this novelty objection is not justified and does not apply to the new claims.

D7 discloses activation of T-cells by fibronectin or vitronectin. However, D7 does not disclose effects by using fragments of fibronectin. Also, serum-free medium is used in the reference only for examining SE release from cells and IL2 production. It is not disclosed to expand T-cells on serum-free medium.

Thus, new claims 1 and 15 are also novel over D7.

2.2 Original claim 17

In section 2.2 of the Communication original claim 17 is objected to as lacking novelty over Cardarelli (D5) and over US 5,354,686 (D6).

This objection does no longer apply since original claim 17 has been cancelled.

2.3 Original claims 18 and 20

In section 2.3 the Examiner also objects to original claims 18 and 20 as lacking novelty over US 5,354,686 (D6) since this document also discloses the possible use of lymphocytes in therapy and their modification by gene therapy.

As regards claim 18, this objection no longer applies since this claim has been cancelled. With respect to original claim 20 (new claim 16) the objection is not justified since this claim refers back to claim 1 which is novel over D6 as set forth in section 2.1(c), supra. Thus, the same applies to new claim 16.

2.4 Original claims 1 to 21 (new claims 1 to 17)

In section 2.4 of the Communication the Examiner cites EP-A1 1 496 109 (D2) as being novelty destroying for original claims 1 to 21. The Examiner takes the position that D2 is novelty destroying because the range of the present application is not sufficiently far from the 5% value known in the art.

This objection does not apply to the new claims because the upper level of "less than 5%" has been changed to "less than 4%".

2.5 Original claims 22 to 24 (new claims 18 to 20)

In section 2.5 of the Communication the Examiner also objects to original claims 22 to 24 as lacking novelty over WO 90/13653 (D3) and over EP-A1 207 751 (D4) arguing that certain sequences disclosed in these documents show more than 98% sequence identity to SEQ ID NO: 25 or 26.

The Applicant takes the position that this objection is not justified and does, in particular, not apply to new claims 18 to 20 which have been further specified to relate to polypeptides/nucleic acids consisting of specific sequences as defined in the claims. In this context we enclose as Annexes I and II, respectively, comparisons of SEQ ID NO: 25 and 26 with the sequences disclosed in D3 and D4, respectively.

Annex I: SEQ ID NO: 25 versus D3 (pFHDEL1)

SEQ ID NO: 25 of the present invention corresponds to only a part of the long sequence disclosed in D3. That is, as shown in Figure 1, SEQ ID NO: 25 is a fragment corresponding to the sequence of D3 positioned at 1239-1885. Accordingly, these polypeptides are quite different from each other as a substance. Further, as noted in the specification, the polypeptide of the present invention having the amino acid sequence of SEQ ID NO: 25 shows very advantageous effects in producing lymphocytes. D3 does not disclose such effects.

Annex II: SEQ ID NO: 26 versus D4 (sequence 7705)

Similar to SEQ ID NO: 25, SEQ ID NO: 26 of the present invention corresponds to only a part of the sequence disclosed in D4, and these polynucleotides are quite different from each other as a substance. Further, as noted in the specification, the polypeptide translated from the polynucleotide shows very advantageous effects in producing lymphocytes. D4 does not disclose such effects.

Thus, Applicant submits that new claims 18 to 20 are novel over D3 and D4.

3. INVENTIVE STEP (ARTICLE 56 EPC)

The claimed subject-matter also involves inventive step over the prior art.

As noted at page 5, line 10 to page 6, line 4 of the specification as "Background Art" in conventional methods for expanding large amounts of lymphocytes, culture mediums containing 5-20% by volume of serum or plasma had been used. In contrast to this, the present invention is based on the finding that the presence of certain fragments of fibronectin enables expanding cytotoxic lymphocytes at a high efficiency even with a smaller amounts of serum or plasma. The present invention is practically very advantageous in the field of cell therapy because the amount of blood from a patient in adoptive immunotherapy can be reduced by lowering the amount of serum or plasma used in the culture medium. Moreover, lymphocytes obtained by the method of the present invention highly express the IL-2 receptor, contain CD8-positive cells in a higher ration, and have higher cytotoxic activity as described at page 11, lines 7 to 13 of the specification. Thus, the present invention exhibits superior effects in the cellular medical field.

None of the above-mentioned cited references provides any hint to expand lymphocytes by lowering the amount of serum or plasma in the culture medium. Moreover, none of the cited prior art references discloses or suggests the use of fibronectin fragments for expanding the lymphocytes.

Finally, none of the cited prior art references provides any hint that any of the above-described advantageous effects as regards the obtained lymphocytes can be obtained. Thus, taken together, it has to be concluded that the claimed subject-matter involves inventive step.

4. RULE 29(3) EPC

In section 3.1 of the Communication original claims 2 to 5 are objected to as only describing an effect.

We submit that this objection is not justified and does, in particular, not apply to the new claims.

In the new claims 2 to 5 it has been clarified that the claimed method is for preparing lymphocytes having a certain property or for achieving a higher expansion.

The indication of a purpose to be achieved in a method step cannot be regarded as being unclear. Namely, it has been accepted by the case law of the Technical Boards of Appeal that a new purpose of a use (e.g. obtaining a new hitherto unrecognized effect) is a technical feature and can confer novelty and inventive step. Moreover, that the indicated effects can indeed be achieved by the claimed method is evident from the specification, e.g., page 11, lines 7 to 13 and the Examples.

5. Requests

With the above explanations and the proposed amendments to the claims, it is submitted that the Applicant has met the requirements as set forth in the Official Communication.

If, however, the Examining Division does not agree to the above, it is requested that either a further Communication pursuant to Article 96(2) EPC or a summons to attend oral proceedings according to Article 116(1) EPC be issued. If deemed expedient, an informal interview is requested. The undersigned is prepared to discuss minor amendments over the telephone.



Dr. Friederike Stolzenburg
European Patent Attorney

Encls.

New claims 1 to 20

Copy of the claims with amendments indicated

Annexes I and II

Amended Claims

1. A method for preparing cytotoxic lymphocytes characterized in that the method comprises the step of carrying out an expansion of cytotoxic lymphocytes using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 4% by volume, in the presence of a fibronectin fragment or a mixture thereof, wherein the fibronectin fragment is at least one polypeptide (m) selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing, or a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).
2. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which highly express an interleukin-2 receptor as compared to cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
3. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which contain CD8-positive cell in a higher ratio as compared to cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
4. The method according to claim 1, wherein the method is for being higher expansion fold as compared to that of a method for preparing cytotoxic lymphocytes in the absence of fibronectin, a fragment thereof or a mixture thereof.
5. The method according to any one of claims 1 to 4, wherein the method is for preparing cytotoxic lymphocytes the cytotoxic activity of which is enhanced or high cytotoxic activity is maintained as compared to a cytotoxic activity of cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

6. The method according to any one of claims 1 to 5, wherein the fibronectin fragment or a mixture thereof is immobilized on a solid phase.
7. The method according to claim 6, wherein the solid phase is a cell culture equipment or a cell culture carrier.
8. The method according to claim 7, wherein the cell culture equipment is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.
9. The method according to any one of claims 1 to 8, wherein the cytotoxic lymphocytes are lymphokine-activated killer cells.
10. The method according to any one of claims 1 to 9, wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.
11. The method according to claim 1 which is carried out in a cell culture equipment, wherein the method satisfies the conditions of:
 - (a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm² to 5 X 10⁵ cells/cm² ; and/or
 - (b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to 5 X 10⁵ cells/mL.
12. The method according to claim 11, wherein the method does not require a step of diluting a cell culture solution.
13. The method according to claim 1, wherein the method comprises carrying out an expansion of cytotoxic lymphocytes in the presence of the fibronectin fragment or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

- (c) a concentration of cells in the cell culture solution being 2×10^5 cells/mL to 1×10^8 cells/mL; or
 - (d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being 1×10^5 cells/cm² to 1×10^8 cells/cm².
14. The method according to claim 1, wherein the method comprises carrying out an expansion of cytotoxic lymphocytes in the presence of the fibronectin fragment or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of the culture or lowered as compared to that at initiation of the culture.
15. A medium for culturing cytotoxic lymphocytes, characterized in that the medium comprises as an effective ingredient the fibronectin fragment or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 4% by volume.
16. The method according to any one of claims 1 to 14, further comprising a step of transducing a foreign gene into cytotoxic lymphocytes.
17. The method according to claim 16, wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.
18. A polypeptide consisting of the amino acid sequence (x) shown in SEQ ID NO: 25 of Sequence Listing or an amino acid sequence (y) having deletion, insertion, addition or substitution of 1-20 amino acid(s) in the amino acid sequence (x), wherein the polypeptide consisting of the amino acid sequence (y) has a function equivalent to that of the amino acid sequence (x).
19. A nucleic acid encoding the polypeptide of claim 18.
20. The nucleic acid according to claim 19, wherein the nucleic acid is (1) a DNA

consisting of the nucleotide sequence shown in SEQ ID NO: 26; or (2) a DNA consisting of a nucleotide sequence having deletion; substitution, insertion or addition of 1-60 nucleotide(s) in the nucleotide sequence shown in SEQ ID NO: 26, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).

Amended Claim

1. A method for preparing a-cytotoxic lymphocytes characterized in that the method comprises the step of carrying out ~~at least one step selected from induction, maintenance and an~~ expansion of a-cytotoxic lymphocytes using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 45% by volume, in the presence of a fibronectin, ~~a fragment thereof or a mixture thereof,~~

wherein the fibronectin fragment is at least one polypeptide (m) selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing, or a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).

2. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which highly expresses an interleukin-2 receptor as compared to a-cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

3. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which contains CD8-positive cell in a higher ratio as compared to a-cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

4. The method according to claim 1, wherein the method is for being higher an-expansion fold ~~is higher as~~ compared to that of a method for preparing a-cytotoxic lymphocytes in the absence of fibronectin, a fragment thereof or a mixture thereof.

5. The method according to any one of claims 1 to 4, wherein the method is for preparing a-cytotoxic lymphocytes the cytotoxic activity of which is enhanced or high cytotoxic activity is maintained as compared to a cytotoxic activity of a-cytotoxic lymphocytes prepared in the absence

of fibronectin, a fragment thereof or a mixture thereof.

6. The method according to any one of claims 1 to 5, wherein the fibronectin, a fragment thereof or a mixture thereof is immobilized on a solid phase.

7. The method according to claim 6, wherein the solid phase is a cell culture equipment or a cell culture carrier.

8. The method according to claim 7, wherein the cell culture equipment is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.

9. The method according to any one of claims 1 to 8, wherein the cytotoxic lymphocytes are a lymphokine-activated killer cells.

~~10. The method according to any one of claims 1 to 9, wherein the fibronectin fragment is a polypeptide (m) comprising at least any one of the amino acid sequences shown in SEQ ID NOs: 1 to 8 of Sequence Listing, or a polypeptide (n) comprising at least one amino acid sequences having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).~~

1011. The method according to any one of claims 1 to 9 10, wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.

~~12. The method according to claim 10, wherein the fibronectin fragment is at least one polypeptide selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing.~~

1113. The method according to claim 1 which is carried out in a cell culture equipment, wherein the method satisfies the conditions of:

(a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm² to 5 X 10⁵ cells/cm² ; and/or

(b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to 5 X 10⁵ cells/mL.

1214. The method according to claim 1143, wherein the method does not require a step of diluting a cell culture solution.

1315. The method according to claim 1, wherein the method comprises carrying out ~~at least any one of induction, maintenance and an~~ expansion of ~~a~~-cytotoxic lymphocytes in the presence of ~~the~~ fibronectin, ~~a fragment thereof~~ or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

(c) a concentration of cells in the cell culture solution being 2 X 10⁵ cells/mL to 1 X 10⁸ cells/mL; or

(d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being 1 X 10⁵ cells/cm² to 1 X 10⁸ cells/cm².

1416. The method according to claim 1, wherein the method comprises carrying out ~~at least any one of induction, maintenance and an~~ expansion of ~~a~~-cytotoxic lymphocytes in the presence of ~~the~~ fibronectin, ~~a fragment thereof~~ or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of the culture or lowered as compared to that at initiation

of the culture.

~~17. A cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.~~

~~18. A medicament comprising as an effective ingredient the cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.~~

1519. A medium for culturing a cytotoxic lymphocytes, characterized in that the medium comprises as an effective ingredient **the fibronectin**, a fragment thereof or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 45% by volume.

1620. The method according to any one of claims 1 to 1416, further comprising a step of transducing a foreign gene into a cytotoxic lymphocytes.

1721. The method according to claim 1620, wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.

1822. A polypeptide ~~having~~ **consisting of** the amino acid sequence (x) shown in SEQ ID NO: 25 of Sequence Listing or an amino acid sequence (y) having deletion, insertion, addition or substitution of 1-20 ~~one or the plural number of~~ amino acid(s) in the amino acid sequence (x), wherein the polypeptide ~~having~~ **consisting of** the amino acid sequence (y) has a function equivalent to that of the amino acid sequence (x).

1923. A nucleic acid encoding the polypeptide of claim 1822.

2024. The nucleic acid according to claim 1923, wherein the nucleic acid ~~comprises is~~ (1) a DNA ~~comprising~~ **consisting of** the nucleotide sequence shown in SEQ ID NO: 26; or (2) a DNA ~~comprising~~ **consisting of** a nucleotide sequence having deletion, substitution, insertion or addition of 1-60 ~~one~~

~~or the plural number of nucleotide(s) in the nucleotide sequence shown in SEQ ID NO: 26, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1), or (3) a DNA which hybridizes to a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26 under stringent conditions, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).~~

FIG. 25

0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150
0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150

FIG. 25	300
160	160
170	170
180	180
190	190
200	200
210	210
220	220
230	230
240	240
250	250
260	260
270	270
280	280
290	290
300	300

[illegible][illegible]

380 NO. 25	750
PERFECT	750
rule	750

[illegible][illegible]

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 25 vs pFHDEL1.ps Date: Wed Aug 15 19:21:12 2007
 Page 2 of 3

SEONO. 25	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
PFHDEL1	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
ruler	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
SEONO. 25	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
PFHDEL1	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
ruler	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
SEONO. 25	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450
PFHDEL1	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450
ruler	1310	1320	1330	1340	1350	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450
SEONO. 25	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
PFHDEL1	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
ruler	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
SEONO. 25	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800	1810	1820	1830	1840	1850
PFHDEL1	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800	1810	1820	1830	1840	1850
ruler	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800	1810	1820	1830	1840	1850
SEONO. 25	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050
PFHDEL1	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050
ruler	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050
SEONO. 25	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250
PFHDEL1	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250
ruler	2110	2120	2130	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 25 vs pFHDEL1.ps Date: Wed Aug 15 19:21:12 2007
Page 3 of 3

SEQUENCE 25 658
pFHDEL1 EVNIGGEPDQSGNGQMSCTGNGPDEKCPERATCPDGGTATGSGQSGATGAGCTCTGGGSECCNCHRGGSPSPSTGQINCSGSEHRTVAVNCECTETPDQADGKDSSE 2231
ruler 2110.....2120.....2130.....2140.....2150.....2160.....2170.....2180.....2190.....2200.....2210.....2220.....2230

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
Page 1 of 8

Seq770510.....20.....30.....40.....50.....60.....70.....80.....90.....100.....110.....120.....130.....140.....150
ruler

Seq7705160.....170.....180.....190.....200.....210.....220.....230.....240.....250.....260.....270.....280.....290.....300
ruler

Seq7705310.....320.....330.....340.....350.....360.....370.....380.....390.....400.....410.....420.....430.....440.....450
ruler

Seq7705460.....470.....480.....490.....500.....510.....520.....530.....540.....550.....560.....570.....580.....590.....600
ruler

Seq7705610.....620.....630.....640.....650.....660.....670.....680.....690.....700.....710.....720.....730.....740.....750
ruler

Seq7705760.....770.....780.....790.....800.....810.....820.....830.....840.....850.....860.....870.....880.....890.....900
ruler

Seq7705910.....920.....930.....940.....950.....960.....970.....980.....990.....1000.....1010.....1020.....1030.....1040.....1050
ruler

Page 3 of 8

[illegible]

Page 4 of 8

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

[illegible]

Table 1

Variable	Mean	SD	Range
Age	60.7	8.9	45-78
Gender			
Male	10		
Female	10		
Marital status			
Married	10		
Single	10		
Divorced	10		
Widowed	10		
Education			
High school or less	10		
College	10		
Postgraduate	10		
Income			
Less than \$10,000	10		
\$10,000-\$20,000	10		
More than \$20,000	10		
Health status			
Excellent	10		
Good	10		
Fair	10		
Poor	10		
Depression			
No depression	10		
Depression	10		

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete each task.

4. The fourth step is to implement the plan. This involves putting the strategy into action and monitoring progress regularly to ensure that the project is on track.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes against the objectives and goals to determine the effectiveness of the project.

[illegible]

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 5 of 8

.....
 Seq7705 4350
 ruler 4350

.....
 Seq7705 4500
 ruler 4500

.....
 Seq7705 4650
 ruler 4650

.....
 Seq7705 4800
 ruler 4800

.....
 Seq7705 4950
 ruler 4950

.....
 Seq7705 5100
 ruler 5100

.....
 Seq7705 5250
 ruler 5250

File: D:\home\14362.CENTRAL f X N g b v\SEQ ID NO 26 vs 7705.ps
Page 6 of 8

[illegible]

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete each task.

4. The fourth step is to implement the plan. This involves assigning tasks to team members, setting deadlines, and monitoring progress to ensure that the project is on track.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes against the objectives and goals to determine the effectiveness of the project and identify areas for improvement.

[illegible]

Table 1. Demographic characteristics of study population

	N (%)
Age group (years)	
<60	79 (8.3)
60-69	100 (10.6)
70-79	100 (10.6)
≥80	100 (10.6)
Total	279 (29.5)
Gender	
Male	100 (10.6)
Female	179 (18.9)
Total	279 (29.5)
Ethnicity	
Chinese	100 (10.6)
Malay	100 (10.6)
Indian	100 (10.6)
Others	100 (10.6)
Total	279 (29.5)
Marital status	
Married	100 (10.6)
Single	100 (10.6)
Widowed	100 (10.6)
Divorced	100 (10.6)
Total	279 (29.5)
Education level	
Primary school or below	100 (10.6)
Secondary school	100 (10.6)
Tertiary school	100 (10.6)
Total	279 (29.5)
Occupation	
Unemployed	100 (10.6)
Retired	100 (10.6)
Employed	100 (10.6)
Total	279 (29.5)

[illegible]

1. The first step in the process of creating a new product is to identify a market need. This involves conducting market research to understand what customers want and what problems they are facing. Once a need is identified, the next step is to develop a concept that addresses this need. This is often done through brainstorming sessions and the creation of a prototype. The concept is then refined through further research and development, leading to the creation of a final product. The final product is then tested in the market to see if it meets the needs of the target audience. If it does, it can be launched as a new product. If not, the process may need to be repeated.

[illegible]

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

2. Once the problem is identified, the next step is to define the objectives and goals of the project. This helps to clarify what needs to be achieved and provides a clear direction for the team.

3. The third step is to develop a plan or strategy to address the problem. This involves breaking down the problem into smaller, manageable tasks and determining the resources needed to complete each task.

4. The fourth step is to implement the plan. This involves putting the strategy into action and monitoring progress regularly to ensure that the project is on track.

5. The final step is to evaluate the results of the project. This involves comparing the actual outcomes with the objectives and goals to determine the effectiveness of the project and identify areas for improvement.

[illegible]

Seq#	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
Seq#	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	8																																																																																																																																													

.....

	1989
BFQ NO. 26
Seq 705
ruler

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 7 of 8

Seq7705
 ruler

Seq7705

Seq7705
 ruler

Seq7705

Seq7705
 ruler

Seq7705

Seq7705
 ruler

Seq7705

Seq7705
 ruler

Seq7705

Seq7705
 ruler

Seq7705

Seq7705
 ruler

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 8 of 8

SEQNO.26
 Seq7705
 ruler

.....

SEQNO.26
 Seq7705
 ruler

.....

SEQNO.26
 Seq7705
 ruler

.....